Gambro gets sales rights in Korea

Gambro gets sales rights in Korea Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading medical technology and healthcare company, has, through its Korean subsidiary, acquired sales rights from Seajin Medicare Corporation, a sales company for certain Cobe products on the Korean market. The sales rights include renal care products of the Cobe brand and blood component technology products of the Cobe BCT brand. Combined the products represent annual sales of about 6 MUSD. The sales operation has about 10 employees whom will join the Gambro organization. Through its subsidiary, Gambro Korea Ltd, Gambro has a leading position on the Korean market. This will be further strengthened through this acquisition whereby Gambro obtains a wholly owned, strongly positioned sales operation on the important Korean market. The acquisition is a further step in Gambro's ongoing strategic initiative to strengthen and consolidate its global leading position in blood component technology and renal care. Mr K.S. Chai, president of Seajin Medicare, will join Gambro Korea Ltd and take up the position as president of the company. He is succeeding Bo-Inge Hansson, who has been appointed President, Gambro Asia Pacific with overall responsibility for Gambro's activities in Asia Pacific, excluding Japan. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46 70 513 65 33 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is the second largest provider of kidney dialysis services in the world. Gambro treats about 42,000 patients in 565 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis fluid. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries. GAMBRO AB TEL +46-8-613 65 00 P.O. Box 7373 FAX +46-8-611 28 30 SE-103 91 STOCKHOLM www.gambro.com SWEDEN info@gambro.com ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/08/02/19990802BIT00150/bit0001.doc http://www.bit.se/bitonline/1999/08/02/19990802BIT00150/bit0002.pdf

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.

Subscribe